fda warning letters compounded semaglutide telehealth 2024 2025 cites companies for CGMP violations, firms for illegally marketing GLP-1 drugs FDA Warns 30 Telehealth Companies

Information sources and search strategy We systematically searched 5 databases: Ovid Medline, Embase, the Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa

Notably, side effects and cost are top reasons for those discontinuing treatment

These trials have enriched the therapeutic landscape for T2D patients, offering a range of GLP-1 receptor agonists with varying cardiovascular profiles, thus allowing clinicians to personalize treatment for each patient

Plans that cover Wegovy typically require prior authorization before approving the prescription

The GLP-1 approach to nutrition prioritizes protein, nutrient density, and sustainable eating patterns that protect muscle while the body loses fat

speaker honorarium from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD and Novo Nordisk